Monte Rosa Therapeutics, Inc. (GLUE) on GreekSoup https://greeksoup.ai/stocks/us/glue/ Every dated entry in the public record on Monte Rosa Therapeutics, Inc.: results, filings, insider trades and the rest, from the filings, the last 90 days. en Fri, 30 Oct 2026 00:00:00 +0000 Monte Rosa Therapeutics, Inc.: short interest 20,660,257 shares at the 15 October 2026 settlement, 11.24 days to coverhttps://greeksoup.ai/stocks/us/glue/short-interest/us:GLUE:short-interest:2026-10-15:dd73eeeb06Thu, 15 Oct 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Monte Rosa Therapeutics, Inc.: Bowen Matthew (Principal Accounting Officer) sold 13 shares at $10.56 on 5 October 2026, $137https://greeksoup.ai/stocks/us/glue/insiders/us:GLUE:insider:2026-10-06:90903d7e89Tue, 06 Oct 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Monte Rosa Therapeutics, Inc. filed 8-K: regulation fd disclosure, other eventshttps://greeksoup.ai/stocks/us/glue/filings/us:GLUE:filing:2026-10-01:3a57a6b594Thu, 01 Oct 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> Monte Rosa Therapeutics, Inc.: short interest 19,686,241 shares at the 30 September 2026 settlement, 18.00 days to coverhttps://greeksoup.ai/stocks/us/glue/short-interest/us:GLUE:short-interest:2026-09-30:89ae5e531dWed, 30 Sep 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Monte Rosa Therapeutics, Inc.: short interest 19,265,990 shares at the 15 September 2026 settlement, 17.08 days to coverhttps://greeksoup.ai/stocks/us/glue/short-interest/us:GLUE:short-interest:2026-09-15:6a86c5728bTue, 15 Sep 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Monte Rosa Therapeutics, Inc. filed 8-K: regulation fd disclosure, other eventshttps://greeksoup.ai/stocks/us/glue/filings/us:GLUE:filing:2026-09-08:465f87b617Tue, 08 Sep 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> Monte Rosa Therapeutics, Inc.: short interest 18,075,786 shares at the 31 August 2026 settlement, 16.56 days to coverhttps://greeksoup.ai/stocks/us/glue/short-interest/us:GLUE:short-interest:2026-08-31:2c21ca3d40Mon, 31 Aug 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Monte Rosa Therapeutics, Inc.: Schedule 13G/A filed by Montanova Capital, LLC, 4.2% of the classhttps://greeksoup.ai/stocks/us/glue/holders/us:GLUE:schedule-13:2026-08-14:ddcc3e8ef8Fri, 14 Aug 2026 00:00:00 +0000Schedule 13D/13GSchedule 13D/13G. The filing. The page on GreekSoup.

]]> Monte Rosa Therapeutics, Inc.: Schedule 13G filed by Vestal Point Capital, LP, 5.4% of the classhttps://greeksoup.ai/stocks/us/glue/holders/us:GLUE:schedule-13:2026-08-14:0f7fc8b67fFri, 14 Aug 2026 00:00:00 +0000Schedule 13D/13GSchedule 13D/13G. The filing. The page on GreekSoup.

]]> Monte Rosa Therapeutics, Inc.: short interest 17,457,317 shares at the 14 August 2026 settlement, 13.99 days to coverhttps://greeksoup.ai/stocks/us/glue/short-interest/us:GLUE:short-interest:2026-08-14:3c275ac82dFri, 14 Aug 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Monte Rosa Therapeutics, Inc. Q2 FY2026 results: revenue $9 million, net income -$43 millionhttps://greeksoup.ai/stocks/us/glue/results/fy2026-q2/us:GLUE:result:2026-08-06:f5f890ef40Thu, 06 Aug 2026 00:00:00 +0000ResultsResults. The filing. The page on GreekSoup.

]]> Monte Rosa Therapeutics, Inc. filed 10-Q: 10-qhttps://greeksoup.ai/stocks/us/glue/filings/us:GLUE:filing:2026-08-06:1c90066c0fThu, 06 Aug 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> Monte Rosa Therapeutics, Inc. filed 8-K: results of operationshttps://greeksoup.ai/stocks/us/glue/filings/us:GLUE:filing:2026-08-06:6fdbbb7001Thu, 06 Aug 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]>